Cytokinetics Incorporated (CYTK)
Symbol Info
Listed Symbol CYTK
Name Cytokinetics Incorporated
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $31,501,000
Latest Fiscal EPS $-1.95
Price Info
21 Day Moving Average $11.6610
21 Day EMA $11.662130
50 Day Moving Average $12.6510
50 Day EMA $12.040830
200 Day EMA $10.677630
200 Day Moving Average 9.998800
52 Week High $14.94
52 Week Low $5.75
52 Week Change $41.002600
Alpha 0.022963
Beta 1.5458
Standard Deviation 0.182201
R2 0.084888
Periods 60
Share Information
10 Day Average Volume 296,535
20 Day Average Volume 379,178
30 Day Average Volume 418,657
50 Day Average Volume 408,577
Outstanding Shares 58,678,894
Float Shares 57,382,149
Percent Float 97.79%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 287
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 4,890,937
Institute Holdings Percent -
Institute Sold Previous 3 Months 2,500,981
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months -
Insider Holdings Percent 2.20%
Insider Sold Previous 3 Months 6
Insiders Shares Owned 1,296,745
Price Change
7 Day Price Change $-0.21
7 Day Percent Change -1.88%
21 Day Price Change $-0.4449997
21 Day Percent Change -3.90%
30 Day Price Change $-2.08
30 Day Percent Change -15.94%
Month To Date Price Change $-0.41
Month To Date Percent -3.60%
90 Day Price Change $-0.259999
90 Day Percent Change -2.32%
Quarter To Date $-0.41
Quarter To Date Percent -3.60%
180 Day Price Change $2.890000
180 Day Percent Change 35.77%
200 Day Price Change $2.920000
200 Day Percent Change 36.27%
Year To Date $4.650000
Year To Date Percent 73.58%
Profile
Description Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatment for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility.
Details
Issue Type CS
Market Cap $643,707,467
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 58,678,894
CEO Robert I. Blum
Employees 130
Last Audit UE
Classification
CIK 0001061983
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 280 East Grand Avenue
South San Francisco, CA 94080
Website http://www.cytokinetics.com
Facisimile +1 650 624-3010
Telephone +1 650 624-3000
Email investor@cytokinetics.com
Key Ratios
Profitability
EBIT Margin -242
EBITDA Margin -240.6
Pre-Tax Profit Margin -288
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $24,978,000
Revenue Per Share $0.4257
Revenue 3 Years $-33.17
Revenue 5 Years $-12.74
Valuation Measures
PE Ratio -
Enterprise Value $548,202,813
Price To Sales 25.770979
Price To Free Cash -10.3
PE High Last 5 Years -
Price To Book 209.9
Price To Cash Flow 2,715.5
PE Low Last 5 Years -
Price To Tangible Book -135.3
Financial Strength
Total Debt To Equity -
Int Coverage -3.6
Current Ratio 8.4
Leverage Ratio -13.7
Quick Ratio 8.3
Long Term Debt To Capital -
Assets
Receivables Turnover 0.9
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -49.37
Return On Equity -312.96
Return On Capital -116.2
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
CYTK
Cytokineti..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.